Spotlight on rivastigmine transdermal patch: In dementia of the alzheimer's type

Drugs and Aging

Volumn 28, Issue 11, 2011, Pages 927-930

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Spotlights; Alzheimers disease; Dementia; Rivastigmine; Transdermal

Indexed keywords

PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; DRUG TOLERABILITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; HUMANS; PHENYLCARBAMATES; TRANSDERMAL PATCH;

EID: 80755159589     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11207090-000000000-00000     Document Type: Article

References (23)

1. Guay DR. Rivastigmine transdermal patch: role in the man-agement of Alzheimer's disease. Consult Pharm 2008 Aug; 23 (8): 598-609
2. Oertel W, Ross JS, Eggert K, et al. Rationale for transder-mal drug administration in Alzheimer disease. Neurology 2007 Jul 24; 69 (4 Suppl. 1): S4-9 (Pubitemid 47205653)
3. Grossberg GT, Sadowsky C, Olin JT. Rivastigmine trans-dermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010; 64 (5): 651-60
4. Novartis Pharmaceuticals Corporation. Exelon® patch (rivastigmine transdermal system): US prescribing information [online]. Available from URL: http://www.phar ma.us.novartis.com/product/pi/pdf/exelonpatch.pdf [Accessed 2010 Nov 24]
5. European Medicines Agency. Exelon® (rivastigmine): sum-mary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document- library/EPA R-Product-Information/human/000169/WC 500032598.pdf [Accessed 2010 Nov 24]
6. Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine trans-dermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther 2008 Jan; 83 (1): 106-14
7. Rakonczay Z. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung 2003; 54 (2): 183-9 (Pubitemid 37105630)
8. Lefevre G, Sedek G, Huang HLA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J Clin Pharmacol 2007 Apr; 47 (4): 471-8 (Pubitemid 46465956)
9. Lefevre G, Buche M, Sedek G, et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009; 49 (4): 430-43
10. Lefevre G, Pommier F, Sedek G, et al. Pharmacokinetics and bioavailability of the novel rivastigmine transdermal patch versus rivastigmine oral solution in healthy elderly subjects. J Clin Pharmacol 2008; 48 (2): 246-52
11. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease-rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007 May; 22 (5): 456-67 (Pubitemid 46831690)
12. Winblad B, Kawata AK, Beusterien KM, et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007 May; 22 (5): 485-91 (Pubitemid 46831693)
13. Schmidt R. A naturalistic study of rivastigmine transdermal patch in outpatient services in Austria [abstract no. P2-245]. 2009 International Conference on Alzheimer's Disease; 2009 Jul 11-16; Vienna
14. Sadowsky CH, Dengiz A, Olin JT, et al. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2009 Jun 31; 24 (3): 267-75
15. Sadowsky CH, Dengiz A, Meng X, et al. Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer's disease: 20-week extension phase results. Prim Care Companion J Clin Psychiatry 2010; 12 (5): e1-8
16. Farlow MR, Alva G, Meng X, et al. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin 2010 Feb; 26 (2): 263-9
17. Grossberg G, Sadowsky C, Forstl H, et al. Safety and tol-erability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009 Apr-Jun; 23 (2): 158-64
18. Lee JH, Sevigny J. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2011 Jan 31; 25 (1): 58-62
19. Winblad B, Grossberg G, Frolich L, et al. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007 Jul 24; 69 (4 Suppl. 1): S14-22 (Pubitemid 47205655)
20. Cummings JL, Farlow MR, Meng X, et al. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease. Clin Drug Invest 2010; 30 (1): 41-9
21. Sadowsky CH, Farlow MR, Meng X, et al. Safety and toler-ability of rivastigmine transdermal patch compared with riv-astigmine capsules in patients switched from donepezil: data from three clinical trials. Int J Clin Pract 2010; 64 (2): 188-93
22. Safirstein B, Meng X, Olin JT. Rivastigmine and con-comitant memantine in Alzheimer's disease: safety and tolerability. CNS Spectr 2010; 15 (9): 594-8
23. Dhillon S. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type. Drugs 2011; 71 (9): 1209-31